Epigenetics Market Opportunity Assessment, Market Challenges, Key vendor analysis, Vendor landscape by 2025
The Global Epigenetics Market is expected to reach US$ 2,611.57 Mn in 2025 from US$ 991.45 in 2017 and estimated to grow with a CAGR of 13.6% from 2018-2025.
(EMAILWIRE.COM, February 08, 2019 ) Epigenetics market is segmented by technology, product, application and end user. Global epigenetics market, based on product the segment is segmented as reagents, kits, enzymes, instruments and consumables and bioinformatics tools. Global epigenetics market, based on the technology was segmented into histone modification, DNA methylation and other technologies. The epigenetics market, based on application was segmented into metabolic diseases, oncology, cardiovascular diseases and other applications. The epigenetics market, based on end user was segmented into contract research organizations, pharmaceutical & biotechnology companies.
Get sample PDF copy at: http://bit.ly/2TDdUc5
The study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence is known as epigenetics. A single or multiple change in phenotype without a changing the genotype which results affects the cells that can read the genes. The report would be of an interest to various stakeholders operating in the epigenetics market. These stakeholders include hospitals, research institutes, medical device suppliers, diagnostic centers, academic institutes, market research, equipment manufacturers, and consulting firms.
The objective of the study is to describe, define, and forecast the epigenetics market by technology, product, application, end user and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall market.
The report analyzes factors affecting epigenetics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the market in these regions. The report also includes the profiles of key epigenetics manufacturing companies along with their SWOT analysis and market strategies.
The prominent players operating in the market of epigenetics across the globe includes Merck KGaA, Thermo Fisher Scientific, Inc., Abcam plc, Agilent Technologies, Active Motif, QIAGEN, Bio-Rad Laboratories, Inc., PerkinElmer Inc., New England Biolabs (NEB), and Illumina, Inc. among others. For instance, in February, 2018 QIAGEN launches epigenetic breast cancer test in Europe. In November 2015 Abcam acquires AxioMx to access new growth opportunities and extend antibody leadership. Thus expanding its business in global epigenetics market.
Buy Now at: http://bit.ly/2TD5H7P
Reason To Buy
Highlights key business priorities in order to assist companies to realign their business strategies
- Highlights Epigenetics Market hereby allowing organizations to gain revenues by focusing majorly on select products
- The key findings and recommendations highlight crucial progressive industry trends in the Epigenetics Market, thereby allowing players across the value chain to develop effective long term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
- Examine the current and future impact of the market and PEST analysis for regions such as North America, Europe, APAC, Middle-East & Africa and South America
Get sample PDF copy at: http://bit.ly/2TDdUc5
The study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence is known as epigenetics. A single or multiple change in phenotype without a changing the genotype which results affects the cells that can read the genes. The report would be of an interest to various stakeholders operating in the epigenetics market. These stakeholders include hospitals, research institutes, medical device suppliers, diagnostic centers, academic institutes, market research, equipment manufacturers, and consulting firms.
The objective of the study is to describe, define, and forecast the epigenetics market by technology, product, application, end user and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall market.
The report analyzes factors affecting epigenetics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the market in these regions. The report also includes the profiles of key epigenetics manufacturing companies along with their SWOT analysis and market strategies.
The prominent players operating in the market of epigenetics across the globe includes Merck KGaA, Thermo Fisher Scientific, Inc., Abcam plc, Agilent Technologies, Active Motif, QIAGEN, Bio-Rad Laboratories, Inc., PerkinElmer Inc., New England Biolabs (NEB), and Illumina, Inc. among others. For instance, in February, 2018 QIAGEN launches epigenetic breast cancer test in Europe. In November 2015 Abcam acquires AxioMx to access new growth opportunities and extend antibody leadership. Thus expanding its business in global epigenetics market.
Buy Now at: http://bit.ly/2TD5H7P
Reason To Buy
Highlights key business priorities in order to assist companies to realign their business strategies
- Highlights Epigenetics Market hereby allowing organizations to gain revenues by focusing majorly on select products
- The key findings and recommendations highlight crucial progressive industry trends in the Epigenetics Market, thereby allowing players across the value chain to develop effective long term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
- Examine the current and future impact of the market and PEST analysis for regions such as North America, Europe, APAC, Middle-East & Africa and South America
Contact Information:
The Insight Partners
Sameer Joshi
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Insight Partners
Sameer Joshi
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results